3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Breast Neoplasms
1
Interventions
Trastuzumab
349
Paclitaxel
310
Cyclophosphamide
286
Docetaxel
267
Carboplatin
215
Capecitabine
214
Letrozole
185
Fulvestrant
178
Doxorubicin
166
Bevacizumab
136
Anastrozole
120
Tamoxifen
117
pertuzumab
114
pembrolizumab
113
Epirubicin
110
exemestane
107
Vinorelbine
106
Gemcitabine
106
Albumin-Bound Paclitaxel
92
Lapatinib
84
130-nm albumin-bound paclitaxel
83
Radiotherapy
79
palbociclib
75
eribulin
73
Cisplatin
69
pyrotinib
66
Taxes
65
Everolimus
55
Goserelin
50
Drug Therapy
50
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
SGN-LIV1A
×
Breast
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled